Brokerages expect Valeritas Holdings, Inc. (NASDAQ:VLRX) to report $5.54 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Valeritas’ earnings. The highest sales estimate is $5.60 million and the lowest is $5.41 million. Valeritas reported sales of $4.80 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 15.4%. The company is expected to issue its next earnings results on Tuesday, February 20th.

On average, analysts expect that Valeritas will report full year sales of $5.54 million for the current year, with estimates ranging from $19.88 million to $20.00 million. For the next fiscal year, analysts expect that the firm will post sales of $27.11 million per share, with estimates ranging from $26.53 million to $27.50 million. Zacks’ sales averages are a mean average based on a survey of research analysts that cover Valeritas.

Separately, ValuEngine raised shares of Valeritas from a “strong sell” rating to a “sell” rating in a research report on Friday, December 1st.

Valeritas (NASDAQ VLRX) opened at $4.04 on Monday. Valeritas has a one year low of $2.00 and a one year high of $40.00. The company has a quick ratio of 3.20, a current ratio of 3.88 and a debt-to-equity ratio of 3.54.

WARNING: This story was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.americanbankingnews.com/2017/12/11/5-54-million-in-sales-expected-for-valeritas-holdings-inc-vlrx-this-quarter.html.

About Valeritas

Valeritas, Inc is a United States-based company, which is engaged in developing and commercializing treatment solutions that contribute to clinical outcomes for patients. The Company’s portfolio includes V-Go disposable insulin delivery device, which is distributed through retail pharmacy. Its V-Go delivers insulin at a continuous preset basal rate and bolus dosing for adults with Type 2 diabetes requiring insulin.

Get a free copy of the Zacks research report on Valeritas (VLRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Valeritas (NASDAQ:VLRX)

Receive News & Ratings for Valeritas Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.